About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.

Looping Whilst Restricting Carbohydrates

Clinicaltrials.gov identifier NCT03932630

Recruitment Status Recruiting

First Posted May 1, 2019

Last update posted December 17, 2019

Study Description

Brief summary:

To investigate the efficacy, safety and utility of hybrid closed-loop glucose control during a low carbohydrate vs. iso-energetic balanced diet in individuals with type 1 diabetes.

  • Condition or Disease:Diabetes
    Type 1 Diabetes
  • Intervention/Treatment: Other: Low carbohydrate diet
    Other: balanced diet
  • Phase: N/A
Detailed Description

Closed-loop systems combining an insulin pump, a glucose sensor and a dosing algorithm that adjusts insulin delivery in a glucose-responsive manner achieve significantly better glucose control than conventional therapy in type 1 diabetes. Achieving satisfactory postprandial glucose control, however, continues to be challenging. The main limitation is the delayed pharmacokinetics and -dynamics of subcutaneously administered insulin with peak actions between 1 and 2 hours. Conversely, glucose levels typically rise within 10minutes following carbohydrate intake. This mismatch largely explains the inability of current closed-loop systems to control postprandial glucose excursions and the increased risk of late postprandial hypoglycaemia in response to both user-derived meal bolus administration and reactive algorithm-driven insulin infusion. Restricting carbohydrate may therefore significantly improve post-prandial glucose control whilst reducing hypoglycaemia. The efficacy of hybrid closed-loop operation in individuals with type 1 diabetes adhering to a low carbohydrate compared to a iso-caloric balanced diet has not been investigated to date.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 15 participants
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Looping Whilst Restricting Carbohydrates (LINEAR) - a Randomised Two-Period Crossover Trial
  • Actual Study Start Date: December 2019
  • Estimated Primary Completion Date: December 2020
  • Estimated Study Completion Date: December 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Study intervention
Other: Low carbohydrate diet
The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
Active Comparator: Control intervention
Other: balanced diet
The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
Outcome Measures
  • Primary Outcome Measures: 1. Percentage of time in target glucose range (3.9 - 10.0 mmol/L) [ Time Frame: 2 weeks ]
    The percentage of time in target glucose range will be assessed using continuous glucose monitoring (CGM).
  • Secondary Outcome Measures: 1. Within day coefficient of variation of glucose (%) [ Time Frame: 2 weeks ]
    Within day coefficient of variation of glucose will be assessed using continuous glucose monitoring (CGM).
  • 2. Between days coefficient of variation of glucose (%) [ Time Frame: 2 weeks ]
    Between days coefficient of variation of glucose will be assessed using continuous glucose monitoring (CGM).
  • 3. Percentage of time above target (>10 mmol/L) [ Time Frame: 2 weeks ]
    The percentage of time below target (>10 mmol/L) will be assessed using continuous glucose monitoring (CGM).
  • 4. Percentage of time below target (<3.9 mmol/L) [ Time Frame: 2 weeks ]
    The percentage of time below target (<3.9 mmol/L) will be assessed using continuous glucose monitoring (CGM).
  • 5. Percentage of time in hypoglycemia (<3.0 mmol/L) [ Time Frame: 2 weeks ]
    The percentage of time in hypoglycemia (<3.0 mmol/L) will be assessed using continuous glucose monitoring (CGM).
  • 6. Hypoglycemia burden quantified as the area under the curve (AUC) with glucose < 3 mmol/L [ Time Frame: 2 weeks ]
    Hypoglycemia burden will be assessed using continuous glucose monitoring (CGM).
  • 7. Percentage of time in hyperglycemia (>16.7 mmol/L) [ Time Frame: 2 weeks ]
    The percentage of time in hyperglycemia (>16.7 mmol/L) will be assessed using continuous glucose monitoring (CGM).
  • 8. Mean glucose levels (mmol/l) [ Time Frame: 2 weeks ]
    Mean sensor glucose levels will be assessed using continuous glucose monitoring (CGM).
  • 9. Total daily insulin dose (U) [ Time Frame: 2 weeks ]
    Total daily insulin dose will be recorded by the insulin pump
  • 10. Daily manual bolus Insulin dose (U) [ Time Frame: 2 weeks ]
    Daily manual bolus insulin dose will be recorded by the insulin pump
  • 11. 2 hour postprandial glucose increment (mmol/) [ Time Frame: 2 weeks ]
    2 hour postprandial glucose increment will be assessed using continuous glucose monitoring (CGM).
  • 12. Within-day standard deviation of glucose (mmol/l) [ Time Frame: 2 weeks ]
    Within-day standard deviation of glucose will be assessed using continuous glucose monitoring (CGM).
  • 13. Night-time percentage of time in target glucose range (3.9 - 10.0 mmol/L) [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Percentage of time in target glucose range will be assessed using continuous glucose monitoring (CGM).
  • 14. Night-time percentage of time above target (> 10.0 mmol/L) [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Percentage of time above target will be assessed using continuous glucose monitoring (CGM).
  • 15. Night-time percentage of time below target (< 3.9 mmol/L) [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Percentage of time below target will be assessed using continuous glucose monitoring (CGM).
  • 16. Night-time percentage of time in hypoglycemia (< 3.0 mmol/L) [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Percentage of time in hypoglycemia will be assessed using continuous glucose monitoring (CGM).
  • 17. Night-time percentage of time in hyperglycemia (> 16.7 mmol/L) [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Percentage of time in hyperglycemia will be assessed using continuous glucose monitoring (CGM).
  • 18. Night-time mean glucose levels [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Mean sensor glucose levels will be assessed using continuous glucose monitoring (CGM).
  • 19. Within night-time standard deviation of glucose (mmol/l)compared to within daytime period (06: - 24:00) standard deviation of glucose (mmol/l) [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Standard deviation of glucose will be assessed using continuous glucose monitoring (CGM).
  • 20. Within nighttime coefficient of variation of glucose(%) [ Time Frame: Between 00:00-06:00 over 2 weeks ]
    Coefficient of variation of glucose (%) will be assessed using continuous glucose monitoring (CGM).
  • 21. Change from baseline in lipid profile [ Time Frame: 2 weeks ]
    Plasma Lipid profile (total Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides)
  • 22. Total daily calorie intake (kcal/day) [ Time Frame: 2 weeks ]
    Total daily calorie intake will be assessed based on photo-documentation of dietary intake
  • 23. Mean beta-hydroxy butyrate level [ Time Frame: 2 weeks ]
    based on download of blood Ketone meter
  • 24. Change from baseline in fasting plasma metabolome [ Time Frame: 2 weeks ]
    Fasting serum sampling
  • 25. Incidence of (serious) adverse events [ Time Frame: 12 weeks ]
    Incidence of severe hypoglycaemia, signficant hyperglycaemia with ketonemia, other SAEs, adverse events, adverse defice effects and device deficiencies
  • 26. Percentage of time when pump was in Auto-mode [ Time Frame: 2 weeks ]
    Based on pump data download
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Female and male subjects aged 18 years or older

- Diabetes mellitus Type 1 as definded by WHO for at least 2 years or C-peptide negative
( 4 mmol/L)

- hybrid-closed-loop Insulin therapy (Minimed 670G) for at least 2 months

- HbA1c 3 units/day for men, > 2 units/day for women)

- Pregnancy, planned pregnancy or breast feeding

- Current participation in another clinical trial

- Total daily insulin dose >2 IU/kg/day

- Nephrolithiasis

- Hereditary dyslipidemia

- Liver steatosis

Contacts and Locations
Contacts

Contact: Lia Bally, MD PhD +41 (0)31 632 36 77 lia.bally@insel.ch

Locations

Switzerland
University Department of Endocrinology, Diabetology, Clinical Nutrition and Metabolism
Bern

Sponsors and Collaborators

University Hospital Inselspital, Berne

Investigators

Principal Investigator: Lia Bally, MD PhD Inselspital, Bern University Hospital, University of Bern

More Information
  • Responsible Party: University Hospital Inselspital, Berne
  • ClinicalTrials.gov Identifier: NCT03932630 History of Changes
  • Other Study ID Numbers: LINEAR
  • First Posted: May 1, 2019 Key Record Dates
  • Last Update Posted: December 17, 2019
  • Last Verified: December 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by University Hospital Inselspital, Berne: artificial pancreas
    hybrid closed-loop
    low carbohydrate diet
    glucose control
  • Additional relevant MeSH terms: Diabetes Mellitus